Balstilimab
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Balstilimab
Jul 19, 2024, 02:00 |
Blog
I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan
"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…
Jul 18, 2024, 15:20 |
Drugs
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…
Jul 5, 2024, 15:53 |
Drugs
Gevorg Tamamyan: Waiting to see promising bot/bal results from our lung cancer trial
Gevorg Tamamyan posted on LinkedIn: "Just saw the presentation from ESMO GI Annual Congress and the…
Jul 1, 2024, 16:15 |
Blog
We need to hurry up, because cancer and patients cannot wait!
Gevorg Tamamyan, the Editor-in-chief of OncoDaily and CEO of Immune Oncology Research Institute, shared on…
Jun 30, 2024, 04:58 |
Blog
Victor Moreno: Botensilimab and balstilimab in treating heavily pre-treated patients with MSS mCRC
Victor Moreno, Director of Clinical Research at START Madrid-FJD, shared a post on LinkedIn: .…
Jun 29, 2024, 11:05 |
Societies
Neoadjuvant botensilimab and balstilimab in colorectal cancer
Smitha Krishnamurthi, Gastrointestinal medical oncologist at Cleveland Clinic, shared on X: "Neoadjuvant botensilimab (1 dose)…
Jun 28, 2024, 15:58 |
Insight
Updates on BOT/BAL from ESMOGI24
ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…
Jun 28, 2024, 13:48 |
Insight
Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24
Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…
Jun 28, 2024, 13:41 |
Insight
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Agenus shared on their X page: "New data from the NEST clinical trial was presented…
Jun 28, 2024, 13:09 |
Insight
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…
Jun 28, 2024, 13:00 |
Insight
Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer
Cathy Eng shared on X/Twitter: "Bot/Bal immunotherapy in colon cancer NEST 1/2. Agenus with very…
Jun 17, 2024, 11:39 |
Insight
Bot/bal in relapsed refractory MSS metastatic colorectal cancer - a quick summary
Arndt Vogel shared a post on X: "Botensilimab plus balstilimab in relapsed/refractory MSS mCRC. Phase…
Jun 14, 2024, 01:23 |
Insight
New Paper Alert! Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab
Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab Authors: Andrea J. Bullock,…
Jun 13, 2024, 17:33 |
Insight
Agenus' Phase 1 clinical trial results have been published in Nature
Agenus shared their publication on investigational immunotherapeutic agents in Nature: "Results from our Phase 1…
May 17, 2024, 11:18 |
Drugs
Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA
Agenus shared on LinkedIn: “Today we announced that Agenus has been granted a Type B…
May 16, 2024, 16:51 |
Insight
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…
May 12, 2024, 03:08 |
Blog
CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals
Agenus shared on LinkedIn: “‘With this infusion of capital, we are poised to accelerate the…
Apr 28, 2024, 05:36 |
Societies
Agenus selected for a poster presentation at the American Society of Clinical Oncology's ASCO2024 Annual Meeting
Quoting Agenus's post on LinkedIn: "Mark your calendars! We have been selected for a poster…
Apr 13, 2024, 06:43 |
Opinion
Agenus announced updated Phase 1 data and progress botensilimab/balstilimab combination in metastatic MSS colorectal cancer
Agenus shared on LinkedIn: "Today we announced updated Phase 1 data and progress on our investigational…
Feb 21, 2024, 12:05 |
Insight
Pashtoon Kasi: See the discussion on our NEST-1trial by Rachna Shroff and Shaalan Beg
Pashtoon Kasi, the Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X/Twitter:…
Feb 14, 2024, 14:59 |
Blog
Yelena Janjigian is leading the investigator-initiated trial of the First Novel Combination of MiNK's Allogeneic Cell Therapy with Agenus' BOT/BAL
Today MiNK Therapeutics released an announcement of the First Refractory Gastric Cancer Patient Dosed in…
Feb 14, 2024, 13:40 |
Insight
Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer
Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn: "Happy to share…
Jan 27, 2024, 15:39 |
Blog
Agenus joined oncology leaders from across the globe at ASCO GI (GI24)
Agenus recently posted on their LinkedIn page: "Agenus joined oncology leaders from across the globe…
Jan 20, 2024, 14:14 |
Drugs
Pashtoon Kasi: Are we on the verge of a new drug combo for colon or rectal cancer?
Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X: "🆕🗞️Just…
Dec 20, 2023, 09:57 |
Blog
Pashtoon Kasi: Our paper with more than 10,000 accesses ranks at N1 in Oncogene Journal
Pashtoon Kasi, the Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X:…
Nov 3, 2023, 12:10 |
Drugs
Steven O'Day shared their recent webinar presented by Endpoints News on “The Next I-O Revolution”
Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn: ''Did you catch our…
Oct 23, 2023, 15:23 |
Drugs
Pashtoon Kasi: So excited to move the field forward with novel therapies for patients with pMMR/MSS Colorectal Cancer
Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital, shared on his Twitter:…
Oct 23, 2023, 13:31 |
Drugs
At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma
Agenus shared on their LinkedIn page: "At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational…
Oct 15, 2023, 19:05 |
Blog
Steven O'Day: I am thrilled to be joining Dr. Benjamin Schlechter, Dr. Pashtoon Kasi, and Phuong Ly-Gallagher for an engaging discussion on “The Next I-O Revolution”.
Sep 21, 2023, 11:16 |
Drugs
Pashtoon Kasi: Are we on the verge of a new drug combo for colorectal cancer?
Pashtoon Kasi, the Director of Colon Cancer Research at Weill Cornell Medicine, shared on X/Twitter:…
Jul 11, 2023, 15:33 |
Drugs
First patient dosed in combination trial of OBT076 and CPI Balstilimab - Oxford BioTherapeutics
We are pleased to announce that the first patient has been dosed in a Phase…
Jul 1, 2023, 06:00 |
Drugs
Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer
In a post by Agenus on Linkedin, it says, "ESMO Late-Breaking GI Data: Agenus’ botensilimab/balstilimab…
Jun 13, 2023, 17:24 |
Insight
In 16 months, we have registered more cancer clinical trials in Armenia, than throughout all the years before that - Gevorg Tamamyan
Last year, on February 4th I was doing a presentation about the cancer clinical trials…
All:
33
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube